Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 After Oral Administration to Healthy Volunteers.

Next Previous
Trial Profile

An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 After Oral Administration to Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 6280 (Primary) ; Flumazenil
  • Indications Anxiety disorders
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

Most Recent Events

  • 09 Dec 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
  • 12 Nov 2008 Trial end date updated, and final date for collection of primary outcome data updated in Trial Comments.
  • 12 Nov 2008 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top